top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 17 minutes ago
  • 1 min read

13/02/2026













Novartis announced Phase 3 data in adult patients with IgA nephropathy (Ref)


Novartis announced final results from its Phase 3 ALIGN/ NCT04573478 study which evaluated Vanrafia (atrasentan; an ETA receptor antagonist) in adult patients with IgA nephropathy (IgAN)


  • The study demonstrated a slowing of kidney function decline in adult patients with IgAN


  • The ALIGN study showed a difference of 2.39 ml/min/1.73m2 in eGFR change from baseline vs. placebo (p = 0.057) at Week 136, four weeks after the end of the study treatment


  • Vanrafia had received accelerated approval in the US and China in 2025 for the reduction of proteinuria in adults with IgAN


  • The safety profile was consistent with previous findings


  • Novartis planned to submit for traditional approval in 2026

bottom of page